After several shareholding conversions, it is now a wholly-owned enterprise of Shanghai Fosun Pharmaceutical (Group) Co. Registered capital: 126.85 million yuan.
Over the years, the company's products have been sold well in China for their excellent quality and high technical content. It has formed four product series, including clinical chemical analysis reagents, enzyme-linked immunoassay reagents, immunoturbidimetric analysis reagents, and supporting reagents for blood gas and electrolyte analyzers, and has become one of the most influential brands of in vitro diagnostic reagents in China, with a sales network all over the country, and is highly praised by the majority of users. At the same time, the technical service centers located in various places facilitate the communication between the company and the users, and meet the users' needs quickly and efficiently.
Fosun Long March has more than 200 employees, with more than 70% of them having higher education. Since its establishment, the company has been awarded the "National Advanced Unit Award in Health Industry" by the Ministry of Health, the "Shanghai Advanced Technology Enterprise Certificate", the "High and New Technology Enterprise" by Shanghai Municipality, and the "Shanghai Advanced Technology Enterprise Certificate" by Shanghai Municipal Science and Technology Commission. Shanghai High-tech Enterprise", "Shanghai Foreign-invested Technology-intensive and Knowledge-intensive Enterprise" and "Innovative Enterprise" issued by Shanghai Science and Technology Commission, "Baoshan District Enterprise Technology Center" issued by Shanghai Municipal Commission of Economy and Information Technology, and "Shanghai Higher Education University" issued by Shanghai University. The company has been awarded the title of "Shanghai Technology Intensive Enterprise with Foreign Investment", "Innovative Enterprise", "Baoshan District Enterprise Technology Center" by Shanghai Municipal Commission of Economy and Informatization, "Shanghai University Star Industrialization Project Certificate", "Star of Invention and Innovation Science and Technology" by the United Nations Technological Information Promotion System (UNTIP) of the Ministry of State of China, and other honorary certificates.
The company has passed the GMP certification of the State Food and Drug Administration and the ISO13485 quality system certification of the EU.
In order to adapt to the rapid development of the company, Fosun Long March has successively held Yaneng Biotechnology (Shenzhen) Company Limited, Shanghai Xingyao Medical Science and Technology Development Company, Shanghai Xingbai Biotechnology Company Limited, and in 2011, through the implementation of the diagnostic base construction project, to play the role of "Long March", In 2011, through the implementation of the diagnostic base construction project, the three advantageous brands of "Long March", "Xingyao" and "Xingbai" are utilized to achieve the purpose of product variety resource integration with a strong R&D team and reference laboratory workstation.
The company has obtained nearly 100 product production approvals and 10 invention patents. The introduced T-cell spotting kit for tuberculosis infection, as the only in-vitro diagnostic reagent authorized to be produced in China for diagnosing tuberculosis infection, has filled the gap in this field in China.
With the increasing improvement of the national medical level, the company will enhance the level of market share through continuous independent research and development, the introduction of foreign advanced technology and the cooperation between industry, academia and research to become a leading enterprise in the diagnostic industry.